Teamed up with Lyell, Juno/WuXi joint venture files IPO betting on China's CAR-T future

Amber Tong

JW Therapeutics got its start on the back of CAR-T tech from Juno Therapeutics, a joint venture banking on the promise of marrying cutting-edge American …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Teamed up with Lyell, Juno/WuXi joint venture files IPO betting on China's CAR-T future

Amber Tong

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Teamed up with Lyell, Juno/WuXi joint ven­ture files IPO bet­ting on Chi­na's CAR-T fu­ture

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Teamed up with Lyell, Juno/WuXi joint venture files IPO betting on China's CAR-T future